Two PROTAC synergy using two E3 ligases for achieving levels of degradation of KRAS G12D not achieved with single PROTACs, ...

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs ...

In a study published in Science, a research team led by Prof. Ye Jian from the Institute of Microbiology of the Chinese ...

Germany-headquartered life science company Evotec on Thursday reported further significant progress in its strategic research ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...

Nurix Therapeutics NRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously untreatable ...

Evotec announced in May of 2022 that the Company has further extended and expanded its collaboration with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...